General Electric ( GE) numbers raised at Morgan Stanley through 2010. Company should continue to deliver strong cash earnings. Overweight rating and new $20 price target. Genzyme ( GENZ) estimates, target lowered at Morgan Stanley. Shares now seen reaching $58. Estimates also cut, as R&D spending remains high and the company will ultimately lose some lucrative patents. Equal-weight rating. Corning ( GLW) estimates raised at Goldman through 2011. Company should benefit from strong demand for PC's and LCD TV sales. Neutral rating and $17 price target. Genuine Parts ( GPC) numbers lowered at Goldman to $41. Estimates also cut, to reflect lower realized EBIT margins. Neutral rating. Harley-Davidson ( HOG) estimates, target boosted at Goldman. Shares of HOG now seen reaching $23. Estimates also raised, to reflect better operating performance in the core motorcycle business. Neutral rating. Mastercard ( MA) estimates raised at Goldman through 2010. Margins are improving, as the consumer remains steady and currency trends are improving. Buy rating and $250 price target. Merck ( MRK) price target up, estimates down at Barclays. Price target raised to $34 from $31. 2009 and 2010 EPS estimates cut to $3.22 from $3.27 and to $3.40 from $3.41, respectively. Reiterate Overweight rating. Netflix ( NFLX) price target raised at Thomas Weisel to $57 from $51. Reiterate Overweight rating. 2009 and 2010 EPS estimates set at $1.77 and $2.07, respectively. Pfizer ( PFE) estimates raised at Credit Suisse. PFE 2009 and 2010 EPS estimates to $2.01 from $1.99 and to $2.42 from $2.23, respectively. Maintain Outperform rating and $21 price target.